Non-Current Assets
PP&E (Net)
Bristol-Myers Squibb PP&E (Net) increased by 1.5% to $7.66B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 6.2%, from $7.21B to $7.66B. Over 5 years (FY 2020 to FY 2025), PP&E (Net) shows an upward trend with a 5.1% CAGR.
Analysis
StatementBalance Sheet Statement
SectionNon-Current Assets
CategoryCapital Allocation
SignalContext dependent
VolatilityStable
First reportedQ4 2014
Last reportedQ1 2026Apr 30, 2026
How to read this metric
Increasing levels suggest ongoing capital investment in manufacturing capacity, while decreasing levels may indicate asset aging or divestitures.
Detailed definition
This represents the net book value of tangible long-lived assets such as manufacturing facilities, laboratories, and equ...
Peer comparison
High capital intensity is common in pharmaceutical manufacturing due to specialized production requirements.
Metric ID:
property_plant_equipment_netHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $5.80B | $5.87B | $6.05B | $6.05B | $5.97B | $6.04B | $6.26B | $6.28B | $6.36B | $6.48B | $6.65B | $6.75B | $6.85B | $6.90B | $7.14B | $7.21B | $7.37B | $7.35B | $7.54B | $7.66B |
| QoQ Change | — | +1.3% | +3.1% | -0.0% | -1.3% | +1.1% | +3.6% | +0.4% | +1.2% | +2.0% | +2.5% | +1.6% | +1.4% | +0.8% | +3.4% | +1.1% | +2.2% | -0.3% | +2.6% | +1.5% |
| YoY Change | — | — | — | — | +3.0% | +2.8% | +3.4% | +3.8% | +6.4% | +7.4% | +6.3% | +7.5% | +7.7% | +6.5% | +7.4% | +6.9% | +7.7% | +6.5% | +5.7% | +6.2% |
Range$5.80B – $7.66B
CAGR+6.0%
Avg YoY Growth+6.0%
Median YoY Growth+6.5%
Current Streak2 quarters growth
Geographic Breakdown — International
| Segment | Q4 '24 |
|---|---|
| International | $2.32B |
| Total | $7.14B |
Geographic Breakdown — United States
| Segment | Q4 '24 |
|---|---|
| United States | $4.81B |
| Total | $7.14B |
PP&E (Net) at Other Companies
Frequently Asked Questions
- What is Bristol-Myers Squibb's pp&e (net)?
- Bristol-Myers Squibb (BMY) reported pp&e (net) of $7.66B in Q1 2026.
- How has Bristol-Myers Squibb's pp&e (net) changed year-over-year?
- Bristol-Myers Squibb's pp&e (net) increased by 6.2% year-over-year, from $7.21B to $7.66B.
- What is the long-term trend for Bristol-Myers Squibb's pp&e (net)?
- Over 5 years (2020 to 2025), Bristol-Myers Squibb's pp&e (net) has grown at a 5.1% compound annual growth rate (CAGR), from $5.89B to $7.54B.
- What does pp&e (net) mean?
- The net value of the company's physical assets like factories and equipment.